Live
- Investors panic over Iran-Israel row
- Jangaon: Congress is for welfare of all people says Kadiyam Kavya
- Yadadri temple trust discloses financial report
- Jana Sena gets relief in AP High Court as party was alloted with glass Tumbler symbol
- Karimnagar: Social media deciding fate of netas and their parties
- Challa Vamsichand Reddy gains support at Shadnagar meeting
- Bhadrachalam: A grand celebration of spirituality and tradition
- April 27 last date for final payment for Haj-2024
- Veerlapalli Shankar leads Mudiraj Community’s support rally for CM
- Irrigation projects: BRS fires failure salvo against TG govt
FDA issues 2 observations for Granules plant
Highlights
Drug firm Granules India on Thursday said the US health regulator has issued two observations after inspection of Chantilly facility of its American arm in Virginia.
Hyderabad: Drug firm Granules India on Thursday said the US health regulator has issued two observations after inspection of Chantilly facility of its American arm in Virginia.
"The United States Food and Drug Administration (USFDA) has completed inspection of the facility of Granules Pharmaceuticals Inc, a wholly-owned foreign subsidiary of the company located in Chantilly, Virginia, USA, on August 21, 2019, with two minor observations," Granules India said in a filing to BSE.
This is a pre-approval inspection for seven products filed from this facility, it added. "Granules Pharmaceuticals Inc will respond to these observations within the stipulated time period," the company said.
Next Story
ADVERTISEMENT
